The King posted the numbers for the "needle movers" of the Dopamine agonist at $12.4 M filed in December 2022 which should have a PDUFA date around October- November 2023 and the Antimetabolite of $42M with a PDUFA date of March 2024.
Considering the delay from final acceptance and launch neither of these two products do not seem to be that significant since Elite can only expect a small share the total $55m market.
I think that Oxycontin with the 517M market is the game changer here along with the increase in Adderall percentages.
That being said, Elite is one of the few OTC companies that have a real P/E ratio.
News 
Market Data 
Discover 
